Unlike single- or dual-receptor peptides, Retatrutide simultaneously targets three key metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
Moreover, the narrow affinity range observed across targets implies a balanced mechanism of action, potentially minimizing systemic side effects common in traditional chemotherapeutics
This results in a more even, radiant tone rather than an artificial lightening effect
Chen YH, Wang CW, Wei MF, Tzeng YS, Lan KH, Cheng AL, et al
Experience glow thats built on science, safety, and real results
It stimulates insulin production, slows down glucagon release (which raises blood sugar), and delays gastric emptying, which helps reduce appetite